{
    "clinical_study": {
        "@rank": "146397", 
        "arm_group": [
            {
                "arm_group_label": "MB12066", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a controlled study to determine the effectiveness and safety of MB12066 in the\n      treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis."
        }, 
        "brief_title": "Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis", 
        "condition": "Nonalcoholic Fatty Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Fibrosis", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NAFLD Activity Score(NAS) \u2265 3 (Biopsy-proven)\n\n        Exclusion Criteria:\n\n          -  Alcohol consumption > 20g/day\n\n          -  Type 1 diabetes or poorly controlled diabetes mellitus (HbA1c \u2265 9%)\n\n          -  Evidence of other chronic liver disease (e.g. HBsAg positive, anti-HCV positive,\n             autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency and etc.)\n\n          -  ALT, AST > 5X the upper limit of normal\n\n          -  Serum creatinine \u2265 2mg/dl\n\n          -  Fibrosis score \u2265 3 according to the NASH CRN fibrosis staging system\n\n          -  NQO1 T/T type\n\n          -  Weight loss of more than 5kg within 6 months\n\n          -  Bariatric surgery within 6 months\n\n          -  Known alcohol or any other drug abuse in the last five years\n\n          -  Insulin sensitizers, hepatoprotective agents, anti-oxidants, lipid-lowering agents,\n             drugs induced fatty liver within 1 month"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029586", 
            "org_study_id": "MB12066_201"
        }, 
        "intervention": [
            {
                "arm_group_label": "MB12066", 
                "description": "oral administration, 100mg bid", 
                "intervention_name": "MB12066 200mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral administration, 100mg bid", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Banpo-daero Seocho-gu", 
                        "zip": "137-701"
                    }, 
                    "name": "Seoul St. Mary's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uijeongbu", 
                        "country": "Korea, Republic of", 
                        "state": "Cheonbo-ro Gyeonggi-do", 
                        "zip": "480-710"
                    }, 
                    "name": "Uijeongbu St. Mary's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Daehak-ro Jongno-gu", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "state": "Dalseong-ro Jung-gu", 
                        "zip": "700-712"
                    }, 
                    "name": "Keimyung University Donsan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "state": "Dongdeok-ro Jung-gu", 
                        "zip": "700-721"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Heukseok-dong Dongjak-gu", 
                        "zip": "156-755"
                    }, 
                    "name": "Chung-ang University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Olympic-ro 43-gil, Songpa-gu", 
                        "zip": "138-736"
                    }, 
                    "name": "ASAN Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Sindaebang-dong Dongjak-gu", 
                        "zip": "156-707"
                    }, 
                    "name": "Boramae Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Wangsimni-ro Seongdong-gu", 
                        "zip": "133-792"
                    }, 
                    "name": "Hanyang University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Yonsei-ro Seodaemun-gu", 
                        "zip": "120-752"
                    }, 
                    "name": "Severance Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis", 
        "overall_contact": {
            "email": "ejlee@ktngls.com", 
            "last_name": "EunJu Lee"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The NAFLD Activity Score (NAS) grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).", 
            "measure": "Change in hepatic steatosis(%)", 
            "safety_issue": "No", 
            "time_frame": "baseline, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029586"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with more than 1 point in total NAFLD Activity Score (NAS)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "measure": "Change in fibrosis score", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "measure": "Change in steatosis score", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12weeks"
            }, 
            {
                "measure": "Change in lobular inflammation score", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12weeks"
            }, 
            {
                "measure": "Change in ballooning score", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12weeks"
            }, 
            {
                "measure": "Change in lipid profile", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4weeks, 8weeks, 12weeks"
            }
        ], 
        "source": "KT&G Life Sciences Corp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "KT&G Life Sciences Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}